We came across a bullish thesis on ReposiTrak, Inc. (TRAK) on “From $100K to $1M” & More’s Substack by YZ and Mark Hogan. In this article we will summarize the bulls’ thesis on TRAK. ReposiTrak, Inc. (TRAK) share was trading at $19.87 as of Sept 19th.
An aerial view of a large warehouse full of food storage containers.
ReposiTrak (TRAK) is a $300M market cap company that provides software solutions to grocery stores, focusing on tracking food supply chains. Its core technology originated from CEO Randall Fields’ Mrs. Fields Cookies, evolving through several iterations, including acquisitions of Prescient in 2009 and Park City Group in 2014. Today, TRAK is known for its food traceability software, which is supported by recurring revenue that has grown at a sustainable 8% CAGR over the last five years. However, overall revenue has declined at a 3% CAGR due to a shift from one-time sales to a SaaS model. Despite this transition, TRAK has maintained GAAP profitability for 34 consecutive quarters, a rarity for small-cap software companies. The company’s cash flow remains robust, with $23M in cash and minimal debt on its balance sheet, providing a fortress-like foundation for future growth.
One of TRAK’s primary growth drivers is its new Traceability software, developed in response to the FDA’s FSMA 204 food traceability law, set to be enforced in 2026. The rollout of this product has dramatically expanded TRAK’s market opportunity, increasing the addressable market size by 15 to 20 times. This growth potential is reinforced by major retailers, such as Kroger, adopting more stringent traceability frameworks, which could set new standards for the food retail industry.
Financially, TRAK is well-positioned with a low leverage ratio of 1.1x total assets over equity. The company has generated $29M in free cash flow over the past decade, translating into a 20% return on invested capital (ROIC), significantly above its estimated 10% cost of capital. This strong cash generation supports ongoing reinvestments in growth while maintaining a conservative capital structure. Stock-based compensation is low, representing just 2% of revenue, and insider ownership is substantial, with insiders holding 42% of outstanding common shares.
From a valuation perspective, TRAK’s current price of $16.73 appears rich relative to its estimated intrinsic value. A discounted cash flow (DCF) analysis suggests a fair value of $10.64, assuming 40% revenue growth over the next few years and an eventual revenue doubling within 2-3 years. TRAK’s price-to-sales (P/S) ratio of 15x places it in the same territory as high-growth companies like ServiceNow, yet the median P/S for small software peers is closer to 2x. However, management’s optimistic projections of $40M in revenue within three years could justify the current valuation, with a more reasonable EPS multiple of 30x pricing the stock at $18/share.
While TRAK faces risks from larger competitors like IBM and Zebra, and potential delays in FDA rule enforcement, its unique position in the traceability market and its strong financials provide a compelling investment case as a long-term opportunity.
ReposiTrak, Inc. is also not on our list of the 31 Most Popular Stocks Among Hedge Funds. As per our database, 5 hedge fund portfolios held TRAK at the end of the second quarter which was 11 in the previous quarter. While we acknowledge the risk and potential of TRAK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TRAK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: Analyst Sees a New $25 Billion “Opportunity” for NVIDIA and 10 Best of Breed Stocks to Buy For The Third Quarter of 2024 According to Bank of America.
Disclosure: None. This article was originally published at Insider Monkey.